Lack of an effect of anacetrapib on the pharmacokinetics of digoxin in healthy subjects

Biopharmaceutics and Drug Disposition

Volumn 32, Issue 9, 2011, Pages 525-529

  Krishna, Rajesh ^a   Stypinski, Daria ^b   Ali, Melissa ^b   Garg, Amit ^a,c   Gendrano III, Isaias Noel ^a   Maes, Andrea ^a,d   Degroot, Bruce ^b   Liu, Yang ^a   Li, Susie ^a   Connolly, Sandra M ^b   Wagner, John A ^a   Stoch, S Aubrey ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b CELERION   (United States)

^c GENENTECH INC   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

anacetrapib; co administration; digoxin

Indexed keywords

ANACETRAPIB; DIGOXIN; GLYCOPROTEIN P;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG EFFECT; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ADOLESCENT; ADULT; AREA UNDER CURVE; CARDIOTONIC AGENTS; CHOLESTEROL ESTER TRANSFER PROTEINS; DIGOXIN; DRUG COMBINATIONS; FEMALE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; OXAZOLIDINONES; YOUNG ADULT;

EID: 82155162318     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.776     Document Type: Article

References (12)

1. Cannon CP, Braunwald E, McCabe CH, et al,. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-1504. (Pubitemid 38477774)
2. Cannon CP, Shah S, Dansky HM,. for the DEFINE Investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010; 363: 2406-2415.
3. Bloomfield D, Carlson GL, Sapre A, et al,. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J 2009; 157: 352.e2-360.e2.
4. Krishna R, Anderson MS, Bergman AJ, et al,. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet 2007; 370: 1907-1914. (Pubitemid 350192656)
5. Gheorghiade M, Harinstein ME, Filippatos GS,. Digoxin for the treatment of chronic and acute heart failure syndromes. Acute Card Care 2009; 11: 83-87.
6. Hinderling PH, Hartmann D,. Pharmacokinetics of digoxin and main metabolites/derivatives in healthy humans. Ther Drug Monit 1991; 13: 381-401.
7. Fenner KS, Troutman MD, Kempshall S, et al,. Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther 2009; 85: 173-181.
8. LANOXIN [GlaxoSmithKline]) Product Circular.
9. Kumar S, Tan EY, Bergman AJ, et al,. Metabolism and disposition of 14 C-anacetrapib, a potent inhibitor of cholesteryl ester transfer protein, in humans. Drug Metab Dispos 2010; 38: 474-483.
10. Denker AE, Morelli G, Vessey LK, et al,. Pharmacokinetics of digoxin in healthy subjects receiving taranabant, a novel cannabinoid-1 receptor inverse agonist. Adv Ther 2009; 26: 230-240.
11. Reuning RH, Geraets DR,. Digoxin. In Applied Pharmacokinetics: Principles of Therapeutics Drug Monitoring, 2nd edn, Evans WE, Schentag JJ, Jusko WJ, (eds). Spokane, WA: Applied Therapeutics Inc; 1986; 570-623.
12. Krishna R, Bergman A, Jin B, et al,. Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Clin Pharmacol Ther 2008; 84: 679-683.